Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Compound trial record
Compound · clinical trials

GW906 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 3 trials in our China register that name GW906 as an intervention. Synced 22 Nov 2026
3Current trials
1Recruiting now
1Lead sponsor
1Country register
At a glance

GW906 is named as an intervention in 3 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Shenzhen Salubris Pharmaceuticals Co., Ltd. The most-studied condition is Hypertension.

Patient leaflets for GW906

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting133%
  • Not yet open133%
  • Active, closed133%

Trials by phase

  • Phase 2267%
  • Not applicable133%
01

Clinical trials of GW906

3 trials
StudyPhaseStatusLead sponsorRegisters
An Extension Trial of GW 906 in Participants With Essential Hypertension
NCT07879755 · ClinicalTrials.gov ↗ · Hypertension
Not applicable Recruiting Shenzhen Salubris Pharmaceuticals Co., Ltd China
A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications
NCT07835984 · ClinicalTrials.gov ↗ · Hypertension
Phase 2 Not yet open Shenzhen Salubris Pharmaceuticals Co., Ltd China
A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension
NCT07835971 · ClinicalTrials.gov ↗ · Hypertension
Phase 2 Active, closed Shenzhen Salubris Pharmaceuticals Co., Ltd China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with GW906

1 condition
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Shenzhen Salubris Pharmaceuticals Co., Ltd3
04

By country register

RegisterTrialsRecruiting
Clinical trials in China31

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about GW906 trials

How many clinical trials are testing GW906?

3 current trials in our China register name GW906 as a drug or biological intervention, as of the registry sync on 22 November 2026. Completed and withdrawn studies are not counted.

Are GW906 trials recruiting patients?

Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors GW906 clinical trials?

The lead sponsor is Shenzhen Salubris Pharmaceuticals Co., Ltd. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how GW906 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GW906 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GW906 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.